InsiderTrades

Form 4 for BEAM Beam Therapeutics Inc.

Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0000950170-24-041432 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2024-04-03 2024-04-01 BEAM Evans John M. CEO, Dir S - Sale $32.13 -18.1K 1.06M -2% -$581.6K
DMT 2024-04-03 2024-04-03 BEAM Evans John M. CEO, Dir A - Grant $0.00 +153.3K 54.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-04-01 S D 18,102 $32.13 1,058,343 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2 Derivative Stock Option (Right to Buy) 2024-04-03 A A 99,336 $0.00 99,336 D $0.67 · 2024-04-03 to 2028-05-08 99,336 Common Stock (F3) On May 8, 2018, the Reporting Person was granted an option to purchase 99,336 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
3 Derivative Stock Option (Right to Buy) 2024-04-03 A A 53,965 $0.00 53,965 D $4.22 · 2024-04-03 to 2029-02-13 53,965 Common Stock (F4) On February 13, 2019, the Reporting Person was granted an option to purchase 53,965 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 53,965 shares.